In addition, we experimentally demonstrated that the combination of IDH inhibitors and EGFR TKIs inhibited lung cancer cell proliferation, which provided novel clues for the clinical management of IDH mutants and especially targeted therapy‐resistant patients. Here, IDH2 is linked to lung carcinoma.